AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03060473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
Study NCT03060473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Ampicillin 2 gm IV every 6 hours for 2 days
Study NCT03060473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Ampicillin 2 gm IV every 6 hours for 2 days
Study NCT03060473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
Study NCT03060473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
Study NCT03108482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-crystal E-58425 (Tramadol/Celecoxib)
Description: Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
Study NCT03108482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol (Ultram®)
Description: Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
Study NCT03108482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex®)
Description: Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
Study NCT03108482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
Study NCT00733967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
Study NCT00733967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo capsules as control.
Study NCT04212117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The Patient Activated Learning System (PALS)
Description: Randomization into PALS arm.
Study NCT04212117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WebMD
Description: Randomization into WebMD arm.
Study NCT02130999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon 20 mg capsule
Study NCT02130999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon 2 mg I.V.
Study NCT00906126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Oral misoprostol
Study NCT04326257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab+Relatlimab
Description: IV administration of both Nivolumab and Relatlimab
Study NCT04326257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab+Ipilimumab
Description: IV administration of both Nivolumab and Ipilimumab
Study NCT00000948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Il-2
Study NCT00000948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: antiretroviral therapy for the treatment of HIV
Study NCT00000948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: antiretroviral therapy for the treatment of HIV
Study NCT06360861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic placenta derived mesenchymal stem cells
Description: Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.
Study NCT03635918 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NightOwl HSAT
Description: Patient wears the NightOwl sensor device
Study NCT04550117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of Intraspinal pressure monitor
Description: A fiberoptic pressure monitoring wire will be placed into the subarachnoid space at the site of traumatic spinal cord injury
Study NCT04905043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
Study NCT04905043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmartPill®
Description: Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
Study NCT04896216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Reduction Intervention
Description: Care providers will complete the Stigma Reduction Intervention curriculum. This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
Study NCT03485586 — intervention group
Intervention type: DEVICE
Intervention: Traditional ultrasound biometrics
Description: To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
Study NCT01242800 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative radiation therapy
Description: Undergo standard palliative radiotherapy
Study NCT01242800 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT03485586 — intervention group
Intervention type: DEVICE
Intervention: Lenstar
Description: To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
Study NCT02097498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Directed feedback
Description: Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
Study NCT02097498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Videolaryngoscopy Videos
Description: Group will watch a series of educational videos related to common airway management errors.
Study NCT04395872 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychiatric counseling
Description: Patients who are admitted to the COVID-19 care unit of the Catholic University of Daegu Hospital are subject to consultation with the psychiatrist. By retrospectively reviewing the medical records of the request and the results of the subjects, We collected Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R) This study evaluates whether there is a difference in psychological scale according to differences in socio-demographic status and medical severity, and compares psychological psychological measures before and after referral to mental health medicine to evaluate the effectiveness of psychiatric counseling.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 0.1-0.2mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin transdermal
Description: 0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole/ Aspirin (Aggrenox)
Description: dipyridamole 200 mg and aspirin 25 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Description: 0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 25- 100 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: 10-30 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: 10-50 mg po. Single dose
Study NCT02177500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan + hydrochlorothiazide
Study NCT02177500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02177500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03336125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D (40µg/day) will be compared with placebo
Study NCT03336125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120 mg olive oil
Study NCT03096535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Individualized cooling protocol.
Study NCT03096535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermoneutral
Description: Thermoneutral control day.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5-100 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Po or patch. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 -125 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: 30-60 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 50-100 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guanfacine
Description: 1-3 mg po. Single dose.
Study NCT00223717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 6-17 g po. Single dose
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: captopril
Description: 25-50 mg PO. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa
Description: 25-200 mg PO. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: 25-200 mg PO. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol tartrate
Description: 25-100 mg PO. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol hydrochloride
Description: 2.5-40 mg PO. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prazosin hydrochloride
Description: 0.5-1 mg PO. Single dose.
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: 0.4-0.8 mg PO. Single dose.
Study NCT00223717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head-up tilt.
Description: Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
Study NCT00223717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: aliskiren (Tekturna) 150-300mg po single dose
Study NCT00223717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local heat stress
Description: Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
Study NCT01526239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening pamphlet
Description: Colorectal cancer screening pamphlet
Study NCT04021329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT Therapy
Description: information added previously
Study NCT00953745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: All subjects will begin on escitalopram and placebo for 8 weeks
Study NCT00953745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
Study NCT00953745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Description: All subjects will begin on escitalopram and placebo capsule for 8 weeks.
Study NCT00953745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
Study NCT03384277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
Study NCT03384277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
Study NCT03384277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 for one dose
Study NCT03384277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
Study NCT01323972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
Description: 4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
Study NCT03229070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval effort group
Description: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
Study NCT03229070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous effort group
Description: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
Study NCT00060762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: 20 sessions of interpersonal therapy were provided over a 6-month period
Study NCT00060762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Treatment
Description: 20 sessions of behavioral weight loss treatment were provided over a 6-month period
Study NCT00060762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self Help
Description: 10 sessions of guided self help were provided over a 6-month period
Study NCT03347097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL
Study NCT03347097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1-TIL
Study NCT00609817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
Study NCT00609817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib/Dexamethasone
Description: Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
Study NCT03258255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: penil or pudendal nerve block in circumcision
Description: regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
Study NCT03328988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
Study NCT01252368 — intervention group
Intervention type: BIOLOGICAL
Intervention: hypertension
Description: patients taking daily ACE inhibitors or sartanes
Study NCT03353077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study NCT03022409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib is an oral agent and will be dosed at 160 mg. Ceralasertib tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
Study NCT03022409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents.
Study NCT03900364 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: partial nephrectomy
Description: Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
Study NCT02965677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Releasing Peripheral Balloon Dilatation Catheter
Description: in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
Study NCT02965677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Balloon Dilatation Catheter
Description: in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
Study NCT03415516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gluma Universal
Description: Adhesive systems
Study NCT03415516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All Bond Universal
Description: Adhesive systems
Study NCT03415516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Bond2
Description: Adhesive systems
Study NCT01217996 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized working memory training program (intervention)
Description: A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
Study NCT01217996 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized working memory training program (control)
Description: Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
Study NCT01988324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDHT-PET scan
Study NCT01988324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-PET scan
Study NCT01988324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT-scan